CORE A: Given the size, complexity, duration, and scope involved. Core A will be fundamental in enabling the successful establishment and operation of the entire program. All costs for administrative support for the Cores and Projects are included here. Dr. James Loyd will assume ultimate administrative responsibility for the management of this Core. Administrative and clerical support for the entire program will be shared by all Project Leaders, Core Leaders and Co-Investigators. This Core will provide and maintain all of the administrative space and functions for the entire program, including but not limited to, offices for all investigators, an administrative area with secretarial and administrative support, a copy/work room, and a conference room with up to date audiovisual amenities. Administrative functions will include ordering of supplies and equipment, maintenance of all records, keeping and monitoring of budgets, maintenance of the personnel database for grant effort, interactions with University administrative offices and the NIH regarding budgetary and other administrative matters, and scheduling and organizing meetings and presentations. This Core will support all of the computer hardware and software resources for the administrative and clerical functions of the program. This Core will coordinate and support the activities of the Internal Advisory Committee and the External Scientific Advisory Board. The basic functions and objectives of the Core include: quality management of program resources, integration of the program, oversight of deliverables within the time frame, assistance with data management, and leading the vision. To achieve these objectives, detailed plans are presented for administrative structure and leadership, project management, external Scientific Advisory Board, and communication/meetings.

Public Health Relevance

Pulmonary arterial hypertension (PAH) is elevated blood pressure in the lungs, which leads to right heart failure and death. No existing treatments are very effective. This Program Project Grant aims to develop new, more effective treatments based on interventions against the hormonal, metabolic, and signaling defects recently shown to form the molecular basis for disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL108800-03
Application #
8692007
Study Section
Special Emphasis Panel (ZHL1-CSR-Q)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$199,585
Indirect Cost
$71,646
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Chen, Xinping; Talati, Megha; Fessel, Joshua P et al. (2016) Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. Circulation 133:82-97
Evans, Jonathan D W; Girerd, Barbara; Montani, David et al. (2016) BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med 4:129-37
Hemnes, Anna R; Zhao, Min; West, James et al. (2016) Critical Genomic Networks and Vasoreactive Variants in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 194:464-75
Talati, Megha H; Brittain, Evan L; Fessel, Joshua P et al. (2016) Mechanisms of Lipid Accumulation in the Bone Morphogenetic Protein Receptor Type 2 Mutant Right Ventricle. Am J Respir Crit Care Med 194:719-28
Hay, Bryan R; Pugh, Meredith E; Robbins, Ivan M et al. (2016) Parenteral Prostanoid Use at a Tertiary Referral Center: A Retrospective Cohort Study. Chest 149:660-6
West, James D; Carrier, Erica J; Bloodworth, Nathaniel C et al. (2016) Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One 11:e0148657
Brittain, Evan L; Talati, Megha; Fessel, Joshua P et al. (2016) Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation 133:1936-44
Chung, Wendy K; Austin, Eric D; Best, D Hunter et al. (2015) When to offer genetic testing for pulmonary arterial hypertension. Can J Cardiol 31:544-7
Hemnes, Anna R; Trammell, Aaron W; Archer, Stephen L et al. (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131:401-9; discussion 409
Newman, John H; Brittain, Evan L; Robbins, Ivan M et al. (2015) Effect of acute arteriolar vasodilation on capacitance and resistance in pulmonary arterial hypertension. Chest 147:1080-5

Showing the most recent 10 out of 37 publications